Results 281 to 290 of about 119,989 (312)
Some of the next articles are maybe not open access.
Adoptive Immunotherapy for Hodgkin's Lymphoma
International Journal of Hematology, 2006Adoptive transfer of tumor-specific T-cells is an attractive strategy for the treatment of patients with refractory or relapsed Hodgkin's lymphoma. However, Hodgkin's lymphomas possess a range of tumor-evasion mechanisms, which must be overcome before the full potential of immunotherapies can be achieved.
Catherine M. Bollard +2 more
openaire +3 more sources
Adoptive immunotherapy of urologic tumors
1989The treatment of humans with advanced cancer represents a major therapeutic challenge. One approach to treating metastatic cancer is immunotherapy, which can be classified into active and passive categories. Active immunotherapy refers to the immunization of the tumor-bearing host with materials that attempt to induce in the host a state of immune ...
Steven A. Rosenberg, Arie S. Belldegrun
openaire +3 more sources
ADOPTIVE IMMUNOTHERAPY IN CANINE CHIMERAS1
Transplantation, 1997Chimerism and tolerance after bone marrow transplantation provide excellent conditions for adoptive immunotherapy with T cells of the marrow donor. We studied adoptive immunotherapy in dog leukocyte antigen-identical canine littermate chimeras. Mixed chimeras were produced by conditioning treatment with total body irradiation of a dose of 10 Gy, a ...
Michael Schumm +5 more
openaire +3 more sources
Adoptive immunotherapy of HCMV infection
Cytotherapy, 2007Human cytomegalovirus (HCMV) infection or reactivation is a frequent cause of morbidity and mortality in immunocompromised individuals such as transplant recipients. Primary HCMV infection or reactivation of HCMV from latency is mostly asymptomatic in immunocompetent individuals and is controlled by the host's cell-mediated immune response.
Götz Ulrich Grigoleit +3 more
openaire +3 more sources
Adoptive Immunotherapy of Advanced Melanoma
Current Treatment Options in Oncology, 2012Adoptive cell therapy (ACT) has emerged as an effective therapy for patients with metastatic melanoma. Since the first introduction of the protocol in 1988 [1], major improvements have been achieved with response rates of 40%-72% among patients who were resistant to previous treatment lines.
Ronnie Shapira-Frommer +2 more
openaire +3 more sources
Costimulatory approaches to adoptive immunotherapy
Current Opinion in Oncology, 1998Costimulation is critical for induction of full T-cell effector function, and thus represents an attractive immunotherapeutic approach for the treatment of cancer. This review examines these approaches, including ex vivo T-cell expansion, systemic "delivery" of constimulation, tumors transduced or transfected with costimulatory ligands, and vaccine ...
Carl H. June +2 more
openaire +3 more sources
Technological advances in adoptive immunotherapy
Drugs of Today, 2005Adoptive immunotherapy is an attractive and elegant strategy for treating a variety of life-threatening diseases. Several approaches have been developed to generate antigen-specific CD4+ and CD8+ T cells for adoptive T-cell therapy in cancer and infectious diseases.
Christine Krueger +2 more
openaire +3 more sources
Enhancing adoptive immunotherapy of cancer
Expert Opinion on Biological Therapy, 2010Conventional therapies, including surgery, chemotherapy and radiotherapy have contributed much to cancer treatment. However, these treatment modalities fail in a large proportion of patients, and there is a great need for effective alternate therapies.
Phillip K. Darcy +6 more
openaire +3 more sources
Mononuclear Cell Adoptive Immunotherapy
Hematology/Oncology Clinics of North America, 1994In contrast with red cells, platelets, and granulocytes, hemotherapy using lymphocytes and monocytes is only beginning to be explored. Blood banks and transfusion services, the traditional sources of expertise in sterile cell processing, storage, and transfusion, have played an integral role in the early technical development of mononuclear cell ...
Harvey G. Klein, Jong-Hoon Lee
openaire +3 more sources
Adoptive Immunotherapy of Melanoma
2011Adoptive immunotherapy involves the ex vivo manipulation and expansion of lymphocytes to treat cancer. These lymphocytes, or effector cells, are “adoptively” transferred into the recipient and may be infused alone or as part of a regimen that includes chemotherapy, radiation therapy, exogenous cytokines and/or other biologic agents (e.g., antibodies ...
Seth M. Pollack, Cassian Yee
openaire +2 more sources